BCAN

Summary

BCAN (brevican, HGNC:23059) is a protein-coding gene on chromosome 1q23.1, encoding Brevican core protein (Q96GW7). May play a role in the terminally differentiating and the adult nervous system during postnatal development.

This gene encodes a member of the lectican family of chondroitin sulfate proteoglycans that is specifically expressed in the central nervous system. This protein is developmentally regulated and may function in the formation of the brain extracellular matrix. This protein is highly expressed in gliomas and may promote the growth and cell motility of brain tumor cells. Alternate splicing results in multiple transcript variants.

Source: NCBI Gene 63827 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 149 total — 1 likely-pathogenic
• MANE Select transcript: NM_021948

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23059
Approved symbol	BCAN
Name	brevican
Location	1q23.1
Locus type	gene with protein product
Status	Approved
Aliases	BEHAB, MGC13038, CSPG7
Ensembl gene	ENSG00000132692
Ensembl biotype	protein_coding
OMIM	600347
Entrez	63827

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 10 protein_coding, 2 nonsense_mediated_decay, 1 retained_intron

ENST00000329117, ENST00000361588, ENST00000424639, ENST00000441358, ENST00000457777, ENST00000479949, ENST00000491823, ENST00000496038, ENST00000884916, ENST00000884917, ENST00000884918, ENST00000884919, ENST00000916621

RefSeq mRNA: 2 — MANE Select: NM_021948 NM_021948, NM_198427

CCDS: CCDS1149, CCDS1150

Canonical transcript exons

ENST00000329117 — 14 exons

Exon	Start	End
ENSE00001802024	156642117	156642275
ENSE00002327966	156659027	156659528
ENSE00002360284	156656938	156657096
ENSE00002407509	156656282	156656389
ENSE00002429428	156657675	156657757
ENSE00002692373	156652248	156652892
ENSE00003507644	156651456	156651689
ENSE00003514828	156648568	156648861
ENSE00003520044	156647983	156648110
ENSE00003541316	156658127	156658271
ENSE00003591119	156658543	156658733
ENSE00003706936	156646047	156646145
ENSE00003711006	156646801	156647175
ENSE00003787078	156647508	156647682

Expression profiles

Bgee: expression breadth ubiquitous, 192 present calls, max score 98.91.

FANTOM5 (CAGE): breadth broad, TPM avg 12.0368 / max 1217.2312, expressed in 283 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
5753	7.1272	243
5754	2.4326	165
5755	1.4867	145
5752	0.9779	112
5756	0.0124	2

Top tissues by expression

274 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	98.91	gold quality
amygdala	UBERON:0001876	97.84	gold quality
anterior cingulate cortex	UBERON:0009835	97.17	gold quality
cingulate cortex	UBERON:0003027	97.14	gold quality
right frontal lobe	UBERON:0002810	96.85	gold quality
nucleus accumbens	UBERON:0001882	96.84	gold quality
caudate nucleus	UBERON:0001873	96.77	gold quality
putamen	UBERON:0001874	96.25	gold quality
ganglionic eminence	UBERON:0004023	96.05	gold quality
prefrontal cortex	UBERON:0000451	95.27	gold quality
Brodmann (1909) area 9	UBERON:0013540	95.24	gold quality
hypothalamus	UBERON:0001898	95.09	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	94.48	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	94.10	gold quality
right hemisphere of cerebellum	UBERON:0014890	93.86	gold quality
neocortex	UBERON:0001950	93.40	gold quality
telencephalon	UBERON:0001893	93.30	gold quality
spinal cord	UBERON:0002240	93.28	gold quality
frontal cortex	UBERON:0001870	93.24	gold quality
Ammon’s horn	UBERON:0001954	93.17	gold quality
cerebellar hemisphere	UBERON:0002245	92.92	gold quality
cerebellar cortex	UBERON:0002129	92.90	gold quality
substantia nigra	UBERON:0002038	92.77	gold quality
cerebral cortex	UBERON:0000956	92.51	gold quality
temporal lobe	UBERON:0001871	92.35	gold quality
cerebellum	UBERON:0002037	91.66	gold quality
midbrain	UBERON:0001891	91.55	gold quality
forebrain	UBERON:0001890	90.81	gold quality
brain	UBERON:0000955	90.75	gold quality
corpus callosum	UBERON:0002336	89.03	gold quality

Single-cell (SCXA)

Detected in 9 experiment(s), a significant marker in 7.

Experiment	Marker?	Max mean expression
E-GEOD-93593	yes	2147.28
E-MTAB-9435	yes	1896.92
E-MTAB-8894	yes	1388.71
E-HCAD-56	yes	701.46
E-GEOD-84465	yes	27.72
E-HCAD-25	yes	26.40
E-MTAB-8142	yes	20.03
E-ENAD-20	no	1041.59
E-ANND-3	no	1.96

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

27 targeting BCAN, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-7152-5P	99.60	69.33	2094
HSA-MIR-5584-5P	99.49	68.22	2814
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-1912-3P	99.32	67.40	936
HSA-MIR-6731-5P	99.28	67.42	2375
HSA-MIR-8085	99.28	67.56	2362
HSA-MIR-3125	99.14	68.49	2269
HSA-MIR-661	99.09	65.94	2062
HSA-MIR-1295B-5P	99.03	67.50	810
HSA-MIR-3916	98.99	68.04	2155
HSA-MIR-6859-5P	98.99	68.07	2049
HSA-MIR-939-3P	98.97	65.07	2347
HSA-MIR-548Q	98.71	65.35	563
HSA-MIR-4436B-3P	98.25	65.26	1494
HSA-MIR-6735-5P	98.24	65.36	1488
HSA-MIR-7843-5P	98.12	65.26	1421
HSA-MIR-4632-5P	97.82	65.38	1470
HSA-MIR-6879-5P	97.77	65.52	1521
HSA-MIR-7106-3P	97.33	65.33	644
HSA-MIR-1291	96.28	65.89	1224
HSA-MIR-6834-5P	96.25	64.88	823

Literature-anchored findings (GeneRIF, showing 9)

• gene locus at chromosome 1q21-23. (PMID:11873941)
• Authors describe the expression of BEHAB/brevican in human brain and characterize two novel glioma-specific isoforms which are generated by differential glycosylation and are absent from normal adult brain and other neuropathologies. (PMID:16061654)
• These results demonstrate for the first time that ADAMTS-5 is capable of degrading brevican and is overexpressed in glioblastoma cells, and suggest that ADAMTS-5 may play a role in glioma cell invasion through the cleavage of brevican. (PMID:16133547)
• The proteoglycan brevican binds to fibronectin after proteolytic cleavage and promotes glioma cell motility (PMID:18611854)
• High Brevican is associated with the invasive phenotype of low-grade astrocytoma. (PMID:21997179)
• Data indicate that median methylation levels of BCAN, HOXD1, KCTD8, KLF11, NXPH1, POU4F1, SIM1, and TCF7L1 were >/=30% higher than in normal samples, representing potential biomarkers for tumor diagnosis. (PMID:22930747)
• The CNS-specific proteoglycan, brevican, and its ADAMTS4-cleaved fragment show differential serological levels in Alzheimer’s disease, other types of dementia and non-demented controls: A cross-sectional study. (PMID:32559242)
• The Role of BEHAB/Brevican in the Tumor Microenvironment: Mediating Glioma Cell Invasion and Motility. (PMID:32845505)
• Serum Brevican as a Biomarker of Cerebrovascular Disease in an Elderly Cognitively Impaired Cohort. (PMID:38254675)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	bcan	ENSDARG00000099412
mus_musculus	Bcan	ENSMUSG00000004892
rattus_norvegicus	Bcan	ENSRNOG00000018798

Paralogs (7): VCAN (ENSG00000038427), NCAN (ENSG00000130287), HAPLN2 (ENSG00000132702), HAPLN3 (ENSG00000140511), HAPLN1 (ENSG00000145681), ACAN (ENSG00000157766), HAPLN4 (ENSG00000187664)

Protein

Protein identifiers

Brevican core protein — Q96GW7 (reviewed: Q96GW7)

Alternative names: Brain-enriched hyaluronan-binding protein, Chondroitin sulfate proteoglycan 7

All UniProt accessions (6): Q96GW7, Q5T3I6, Q5T3I7, Q5T3I8, V9GXZ8, V9GY88

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in the terminally differentiating and the adult nervous system during postnatal development. Could stabilize interactions between hyaluronan (HA) and brain proteoglycans.

Subunit / interactions. Interacts with TNR.

Subcellular location. Secreted Secreted. Extracellular space. Extracellular matrix Membrane.

Tissue specificity. Expressed in the retina, specifically in the inner nuclear layer, inner plexiform layer and ganglion cell layer (at protein level). Detected in cerebrospinal fluid (at protein level). Detected in urine (at protein level).

Post-translational modifications. O-glycosylated; contains chondroitin sulfate. O-glycosylated with a core 1 or possibly core 8 glycan.

Similarity. Belongs to the aggrecan/versican proteoglycan family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96GW7-1	1	yes
Q96GW7-2	2

RefSeq proteins (2): NP_068767, NP_940819 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000436	Sushi_SCR_CCP_dom	Domain
IPR000538	Link_dom	Domain
IPR000742	EGF	Domain
IPR001304	C-type_lectin-like	Domain
IPR003006	Ig/MHC_CS	Conserved_site
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013106	Ig_V-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR016186	C-type_lectin-like/link_sf	Homologous_superfamily
IPR016187	CTDL_fold	Homologous_superfamily
IPR018378	C-type_lectin_CS	Conserved_site
IPR035976	Sushi/SCR/CCP_sf	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR050691	Hyaluronan_bind_Proteoglycan	Family

Pfam: PF00008, PF00059, PF00084, PF00193, PF07686

UniProt features (39 total): disulfide bond 13, domain 6, glycosylation site 5, region of interest 4, compositionally biased region 2, splice variant 2, sequence variant 2, signal peptide 1, chain 1, modified residue 1, sequence conflict 1, lipid moiety-binding region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96GW7-F1	70.06	0.42

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 418, 646

Disulfide bonds (13): 57–137, 179–250, 203–224, 277–352, 301–322, 650–661, 655–670, 672–681, 688–699, 716–808, 784–800, 815–858, 844–871

Glycosylation sites (5): 130, 337, 418, 905, 906

Function

Pathways and Gene Ontology

Reactome pathways

12 pathways

ID	Pathway
R-HSA-1474228	Degradation of the extracellular matrix
R-HSA-1971475	Glycosaminoglycan-protein linkage region biosynthesis
R-HSA-2022870	CS-GAG biosynthesis
R-HSA-2022923	DS-GAG biosynthesis
R-HSA-2024101	CS/DS degradation
R-HSA-3000178	ECM proteoglycans
R-HSA-3560783	Defective B4GALT7 causes EDS, progeroid type
R-HSA-3560801	Defective B3GAT3 causes JDSSDHD
R-HSA-3595172	Defective CHST3 causes SEDCJD
R-HSA-3595174	Defective CHST14 causes EDS, musculocontractural type
R-HSA-3595177	Defective CHSY1 causes TPBS
R-HSA-4420332	Defective B3GALT6 causes EDSP2 and SEMDJL1

MSigDB gene sets: 126 (showing top): BENPORATH_ES_WITH_H3K27ME3, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GOBP_FOREBRAIN_DEVELOPMENT, RODWELL_AGING_KIDNEY_NO_BLOOD_DN, WEI_MYCN_TARGETS_WITH_E_BOX, GOBP_CELL_JUNCTION_ORGANIZATION, GOBP_HIPPOCAMPUS_DEVELOPMENT, BLALOCK_ALZHEIMERS_DISEASE_UP, GOBP_PALLIUM_DEVELOPMENT, GOBP_HEAD_DEVELOPMENT, GOMF_GLYCOSAMINOGLYCAN_BINDING, GOBP_TELENCEPHALON_DEVELOPMENT, EBAUER_MYOGENIC_TARGETS_OF_PAX3_FOXO1_FUSION, GOBP_LIMBIC_SYSTEM_DEVELOPMENT

GO Biological Process (5): skeletal system development (GO:0001501), cell adhesion (GO:0007155), central nervous system development (GO:0007417), hippocampus development (GO:0021766), synapse maturation (GO:0060074)

GO Molecular Function (3): hyaluronic acid binding (GO:0005540), carbohydrate binding (GO:0030246), protein binding (GO:0005515)

GO Cellular Component (10): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), Golgi lumen (GO:0005796), lysosomal lumen (GO:0043202), synapse (GO:0045202), perineuronal net (GO:0072534), side of membrane (GO:0098552), glutamatergic synapse (GO:0098978), membrane (GO:0016020), extracellular matrix (GO:0031012)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Diseases associated with glycosaminoglycan metabolism	6
Chondroitin sulfate/dermatan sulfate metabolism	3
Extracellular matrix organization	2
Glycosaminoglycan metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
system development	2
nervous system development	2
binding	2
cellular process	1
pallium development	1
limbic system development	1
anatomical structure development	1
developmental maturation	1
synapse organization	1
carboxylic acid binding	1
Golgi apparatus	1
intracellular organelle lumen	1
lysosome	1
vacuolar lumen	1
cell junction	1
perisynaptic extracellular matrix	1
membrane	1
leaflet of membrane bilayer	1
synapse	1
external encapsulating structure	1

Protein interactions and networks

STRING

1886 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
BCAN	PTPRZ1	P23471	988
BCAN	ACAN	P16112	983
BCAN	VCAN	P13611	909
BCAN	NCAN	O14594	908
BCAN	NRCAM	Q92823	679
BCAN	ADAMTS5	Q9UNA0	669
BCAN	FN1	P02751	669
BCAN	ADAMTS4	O75173	667
BCAN	SPTBN4	Q9H254	655
BCAN	LUM	P51884	650
BCAN	FMOD	Q06828	650
BCAN	PVALB	P20472	629
BCAN	HAPLN4	Q86UW8	617
BCAN	CD44	P16070	617
BCAN	ADAMTS8	Q9UP79	614
BCAN	NFASC	O94856	614

IntAct

21 interactions, top by confidence:

A	B	Type	Score
APLP2	BCAN	psi-mi:“MI:0915”(physical association)	0.560
CSNK1D	BCAN	psi-mi:“MI:0915”(physical association)	0.560
BCAN	LYN	psi-mi:“MI:0915”(physical association)	0.560
APP	BCAN	psi-mi:“MI:0915”(physical association)	0.560
APP	BCAN	psi-mi:“MI:0407”(direct interaction)	0.440
	BCAN	psi-mi:“MI:0915”(physical association)	0.370
PRNP	CARNS1	psi-mi:“MI:0914”(association)	0.350
PRNP	WDR91	psi-mi:“MI:0914”(association)	0.350
BCAN	VCAN	psi-mi:“MI:0914”(association)	0.350
BCAN	HSPA5	psi-mi:“MI:0914”(association)	0.350
BCAN	LAMA5	psi-mi:“MI:0914”(association)	0.350
BCAN	PCBD1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (37): FBXO11 (Affinity Capture-MS), VCAN (Affinity Capture-MS), ULK3 (Affinity Capture-MS), REPIN1 (Affinity Capture-MS), CCNYL1 (Affinity Capture-MS), VCAN (Affinity Capture-MS), ULK3 (Affinity Capture-MS), CCNYL1 (Affinity Capture-MS), FBLN2 (Reconstituted Complex), BCAN (Affinity Capture-MS), BCAN (Biochemical Activity), BCAN (Biochemical Activity), BCAN (Biochemical Activity), BCAN (Biochemical Activity), BCAN (Biochemical Activity)

ESM2 similar proteins: A1L0T3, A1L4H1, A6QNY1, D3YZF7, O95428, P28698, P30203, P55068, P55106, P59222, P98162, Q04756, Q14767, Q28019, Q28062, Q28256, Q28343, Q28670, Q3U515, Q4G0T1, Q5F378, Q5HZW5, Q61003, Q61361, Q6H9L7, Q6KF10, Q6PGE4, Q6QNF4, Q7TQH7, Q7Z4F1, Q86T13, Q86VR7, Q86VZ4, Q8BV57, Q8BZE1, Q8CB67, Q8VCP9, Q8WTU2, Q91V98, Q96DN2

Diamond homologs: A0ZT93, B0VXV2, B4XT08, B5U6Y6, B5U6Y7, C0HKZ7, O60449, P05140, P06027, P06734, P0DJL5, P10716, P13611, P14371, P20693, P34472, P55066, P55067, P81018, P81282, P81996, Q01758, Q02988, Q26627, Q28062, Q28670, Q28858, Q4PRD0, Q4TU93, Q4V885, Q61830, Q62059, Q64449, Q66S03, Q6X5S2, Q6X5S3, Q6X5S5, Q6X5S6, Q6X5S7, Q6X5S8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

149 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	132
Likely benign	8
Benign	3

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
149564	GRCh38/hg38 1q22-23.1(chr1:156256495-156681863)x1	Likely pathogenic

SpliceAI

2374 predictions. Top by Δscore:

Variant	Effect	Δscore
1:156646032:A:AG	acceptor_gain	1.0000
1:156646032:AT:A	acceptor_gain	1.0000
1:156646033:T:G	acceptor_gain	1.0000
1:156646033:T:TA	acceptor_gain	1.0000
1:156646041:T:TA	acceptor_gain	1.0000
1:156646045:A:AG	acceptor_gain	1.0000
1:156646046:G:GA	acceptor_gain	1.0000
1:156646046:GC:G	acceptor_gain	1.0000
1:156646046:GCC:G	acceptor_gain	1.0000
1:156646046:GCCT:G	acceptor_gain	1.0000
1:156646142:TCAGG:T	donor_loss	1.0000
1:156646145:GGT:G	donor_loss	1.0000
1:156646146:G:GA	donor_loss	1.0000
1:156646146:G:GG	donor_gain	1.0000
1:156647171:CAAAG:C	donor_loss	1.0000
1:156647172:AAAGG:A	donor_loss	1.0000
1:156647173:AAGGT:A	donor_loss	1.0000
1:156647506:AGG:A	acceptor_gain	1.0000
1:156647507:GGG:G	acceptor_gain	1.0000
1:156647979:CTA:C	acceptor_loss	1.0000
1:156647981:A:AC	acceptor_loss	1.0000
1:156647981:A:AG	acceptor_gain	1.0000
1:156647981:AG:A	acceptor_gain	1.0000
1:156647982:G:A	acceptor_loss	1.0000
1:156647982:G:GG	acceptor_gain	1.0000
1:156647982:GG:G	acceptor_gain	1.0000
1:156647982:GGT:G	acceptor_gain	1.0000
1:156647982:GGTA:G	acceptor_gain	1.0000
1:156647982:GGTAT:G	acceptor_gain	1.0000
1:156648080:GATGT:G	donor_gain	1.0000

AlphaMissense

5818 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:156647660:T:A	W207R	1.000
1:156647660:T:C	W207R	1.000
1:156647662:G:C	W207C	1.000
1:156647662:G:T	W207C	1.000
1:156648713:G:C	W305C	1.000
1:156648713:G:T	W305C	1.000
1:156658141:G:C	W769C	1.000
1:156658141:G:T	W769C	1.000
1:156646944:T:A	W79R	0.999
1:156646944:T:C	W79R	0.999
1:156646946:G:C	W79C	0.999
1:156646946:G:T	W79C	0.999
1:156647112:T:G	Y135D	0.999
1:156647118:T:A	C137S	0.999
1:156647118:T:C	C137R	0.999
1:156647119:G:C	C137S	0.999
1:156647577:G:A	C179Y	0.999
1:156647648:T:A	C203S	0.999
1:156647649:G:A	C203Y	0.999
1:156647649:G:C	C203S	0.999
1:156648011:T:A	C224S	0.999
1:156648011:T:C	C224R	0.999
1:156648012:G:A	C224Y	0.999
1:156648012:G:C	C224S	0.999
1:156648013:T:G	C224W	0.999
1:156648090:G:A	C250Y	0.999
1:156648091:T:G	C250W	0.999
1:156648680:G:C	W294C	0.999
1:156648680:G:T	W294C	0.999
1:156648711:T:A	W305R	0.999

dbSNP variants (sampled 300 via entrez): RS1000147163 (1:156655957 T>C), RS1000166226 (1:156656727 G>C,T), RS1000277130 (1:156650834 T>A), RS1000329119 (1:156658322 G>C), RS1000429503 (1:156644536 T>A), RS1000595108 (1:156652196 G>A,T), RS1000734600 (1:156645818 G>A,T), RS1001108579 (1:156655049 G>T), RS1001365352 (1:156642626 CG>C), RS1001944369 (1:156659668 T>A,C), RS1001998526 (1:156659990 C>T), RS1002159081 (1:156653990 G>A,C,T), RS1002419375 (1:156641532 C>T), RS1002776771 (1:156641246 A>G), RS1003231751 (1:156648175 C>T)

Disease associations

OMIM: gene MIM:600347 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST006585_46	Blood protein levels	6.000000e-12

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression	2
Benzo(a)pyrene	increases expression, affects methylation, decreases methylation	2
Valproic Acid	increases expression	2
FR900359	decreases phosphorylation	1
aminomethylphosphonic acid (AMPA)	decreases expression	1
methylmercuric chloride	decreases expression	1
bisphenol A	affects cotreatment, increases methylation	1
titanium dioxide	increases expression	1
arsenite	increases methylation	1
perfluorooctane sulfonic acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
NSC 689534	affects binding, increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Decitabine	affects expression	1
Sunitinib	increases expression	1
Fulvestrant	increases methylation, affects cotreatment	1
Cisplatin	affects expression	1
Copper	affects binding, increases expression	1
Estradiol	increases expression	1
Lead	affects expression	1
Phenylmercuric Acetate	affects cotreatment, increases expression	1
Plant Extracts	decreases expression, affects cotreatment	1
Tobacco Smoke Pollution	increases expression	1
Urethane	decreases expression	1
2,4-Dichlorophenoxyacetic Acid	decreases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	increases expression	1
Asbestos, Crocidolite	increases expression	1
Okadaic Acid	decreases expression	1
Acrylamide	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.